Tiziana Life Sciences PLC Result of Annual General Meeting (1606D)
25 Junio 2021 - 4:40AM
UK Regulatory
TIDMTILS
RNS Number : 1606D
Tiziana Life Sciences PLC
25 June 2021
THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS INSIDE
INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION
596/2014
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN
PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD
CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH
JURISDICTION
Tiziana Life Sciences plc
(the "Company")
Result of Annual General Meeting
At the Annual General Meeting of the Company held at 10.00 a.m.
on 25 June 2021, all of the resolutions were duly passed.
The results of the proxy voting will be available shortly on the
Company's website,
https://ir.tizianalifesciences.com/shareholder-services/annual-general-meeting.
The Company also confirms that it has re-activated its strategic
plan to redomicile to Bermuda; shareholders will receive further
information in due course.
The person who arranged for the release of this announcement was
Keeren Shah, Chief Financial Officer.
About Tiziana Life Sciences
Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS) is a UK
biotechnology company that focuses on the discovery and development
of novel molecules to treat human disease in oncology and
immunology. In addition to Milciclib (a CDK inhibitor being
developed in oncology), the Company is also developing Foralumab in
COVID-19, multiple sclerosis, and Crohns Disease. Foralumab is the
only second generation fully human anti-CD3 monoclonal antibody in
clinical development in the world. This Phase 2 compound has
potential application in a wide range of autoimmune and
inflammatory diseases, such as nonalcoholic steatohepatitis (NASH),
ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D),
Crohn's disease, psoriasis and rheumatoid arthritis, where
modulation of a T-cell response is desirable. The Company is
accelerating development of anti-Interleukin 6 receptor (IL6R) mAb,
a fully human monoclonal antibody for treatment of IL6-induced
inflammatory pulmonary diseases.
For further enquiries:
United Kingdom:
Tiziana Life Sciences
plc
Gabriele Cerrone,
Chairman and founder +44 (0)20 7495 2379
United States:
Investors:
Dave Gentry, CEO
RedChip Companies
Inc.
1-800-RED-CHIP (733-2447)
or
407-491-4498
dave@redchip.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RAGDKPBNCBKKCAB
(END) Dow Jones Newswires
June 25, 2021 05:40 ET (09:40 GMT)
Tiziana Life Sciences (LSE:TILS)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Tiziana Life Sciences (LSE:TILS)
Gráfica de Acción Histórica
De May 2023 a May 2024